Atara Biotherapeutics Inc (NASDAQ: ATRA) on Friday, plunged -21.62% from the previous trading day, before settling in for the closing price of $17.44. Within the past 52 weeks, ATRA’s price has moved between $5.01 and $19.15.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -15.00%. The company achieved an average annual earnings per share of 124.75%. With a float of $4.16 million, this company’s outstanding shares have now reached $7.21 million.
Atara Biotherapeutics Inc (ATRA) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Atara Biotherapeutics Inc is 42.24%, while institutional ownership is 26.29%. The most recent insider transaction that took place on Nov 17 ’25, was worth 38,437. In this transaction President and CEO of this company sold 2,915 shares at a rate of $13.19, taking the stock ownership to the 64,974 shares. Before that another transaction happened on Nov 17 ’25, when Company’s Chief Accounting Officer sold 1,804 for $13.19, making the entire transaction worth $23,788. This insider now owns 33,454 shares in total.
Atara Biotherapeutics Inc (ATRA) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -1.19 earnings per share (EPS) for the period topping the consensus outlook (set at -3.49) by 2.3. Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.46 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 124.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 45.42% during the next five years compared to -15.00% drop over the previous five years of trading.
Atara Biotherapeutics Inc (NASDAQ: ATRA) Trading Performance Indicators
Atara Biotherapeutics Inc (ATRA) is currently performing well based on its current performance indicators. A quick ratio of 1.02 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.19, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach 0.40 in one year’s time.
